CMTx Biotech
Brad Zerler is on the Board of Advisors at CMTx Biotech.
This person is not in the org chart
This person is not in any offices
CMTx Biotech
CMTx Biotech is a clinical-stage biopharmaceutical company that is developing an orally administered small molecule for the treatment of sepsis patients at risk of Acute Respiratory Distress Syndrome (ARDS) and/or Multiple Organ Dysfunction Syndrome (MODS), including those infected with SARS-CoV-2 (COVID-19).